Market research
HG6.F Mayne Pharma Group Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 139M
- P/E ratio
- Not available
- Analyst target
- Not available
- Beta
- Not available
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Distribution
- ISIN
- AU000000MYX0
- Market cap
- 139M
- P/E ratio
- Not available
- Analyst target
- Not available
- Beta
- Not available
About
About Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HG6.F discussion.
5 years, 5 months ago
Mayne Pharma Group Limited is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Mayne Pharma Group Limited's total revenue sank by 0.0% to $114M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.3% to $20M since the same quarter in the previous year.
Based on the above factors, Mayne Pharma Group Limited gets an overall score of 1/5.